Sun, Oct 26, 2014, 12:32 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Galena Biopharma, Inc. Message Board

  • decemberblitz decemberblitz Jul 3, 2013 10:49 AM Flag

    For Serious Investors - Roche Will Buy Galena

    Today's announcement on Perjeta solidifies to me now it is ONLY a matter of Time. I suspect after interim results of the Phase 2b study of NeuVax/Herceptin - scheduled for Sept 2014 just before Herceptin patent expires in Europe.

    - We all know Herceptin, it is designed for patients with LATE-STAGE (metastatic - tumor grade 2 or 3) HER2-POSITIVE breast cancer.
    - T-DM1 - for the treatment of patients with HER2-POSITIVE, unresectable locally ADVANCED (metastatic) breast cancer who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy.
    - Kadcyla - pretreated HER2-POSITIVE ADVANCED (metastatic) breast cancer
    - Perjeta (pertuzumab) - just filed today to be a neoadjuvant treatment in patients with HER2-POSITIVE, EARLY-STAGE breast cancer. The company said the US regulator is expected to render its decision by October 31.

    Roche has a lot of work ongoing in the breast cancer space, specifically in patients who are HER2-POSITIVE. Just read about how they have EARLY and LATE-STAGE POSITIVE covered. But you may be asking what are they working on for patients who are HER2-NEGATIVE?

    Roche has NOT had much success in the U.S. in the HER2-NEGATIVE patients. Avastin was FDA approved for ADVANCED (metastatic) breast cancer until the FDA ruled to withdraw the breast cancer indication in November 2011. It caused adverse effects including severe high blood pressure and hemorrhaging.

    With NeuVax in their portfolio, Roche will be able to treat ALL breast cancer patients at any stage. NeuVax alone will treat those with EARLY-STAGE NEGATIVE and combined with Herceptin it will treat those with LATE-STAGE NEGATIVE patients.

    Only a matter of time and it will be interesting to see what Teva will do - I imagine they will enter into a bidders war and drive up the price but Roche has so much more to gain so they will prevail.

    Long and strong Galena.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.90+0.01(+0.53%)Oct 24 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.